Literature DB >> 25190263

Gaps in recognition and evaluation of incidentally identified hepatic steatosis.

Andrew P Wright1, Amit P Desai, Surabhi Bajpai, Lindsay Y King, Dushyant V Sahani, Kathleen E Corey.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD), the most common cause of liver disease, is frequently diagnosed incidentally on imaging. The goal of the present study was to characterize rates of documentation and evaluation of incidentally identified steatosis.
METHODS: Adults who underwent abdominal computed tomography with incidentally reported steatosis from January 2008 to October 2011 and with ≥1 primary care appointment within 14 months following imaging were included.
RESULTS: One hundred twenty-seven individuals with newly identified steatosis on imaging were included. Medical record documentation of newly identified steatosis occurred in only 29 individuals (22.8 %). Mention of steatosis within the "impression" section of radiology reports in addition to the report body was associated with significantly higher likelihood of primary care documentation (p = 0.007). Primary care documentation of steatosis was associated higher rates of evaluation for the etiology of steatosis include testing of aminotransferase levels (96.5 vs. 77.5 %, p = 0.025), alcohol use screening (89.6 vs. 66.3 %, p = 0.02), and hepatitis C screening (20.6 vs. 2.0 %, p = 0.002). No patient had documentation of the NAFLD fibrosis score and none were referred for specialist evaluation or for liver biopsy. However, when calculated, the NAFLD fibrosis score identified 14 patients (11 %) as high risk for advanced hepatic fibrosis.
CONCLUSION: Documentation of incidentally identified steatosis is infrequent but was improved when steatosis was mentioned in the "impression" of radiographic reports. Documentation of steatosis was associated with increased rates of aminotransferase testing and alcohol use and hepatitis C screening. An important proportion of individuals with incidentally identified steatosis are at high risk of fibrosis and may benefit from additional evaluation.

Entities:  

Mesh:

Year:  2014        PMID: 25190263      PMCID: PMC4385713          DOI: 10.1007/s10620-014-3346-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  10 in total

1.  The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal
Journal:  Gastroenterology       Date:  2012-05-15       Impact factor: 22.682

Review 2.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

3.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

Authors:  Zobair M Younossi; Maria Stepanova; Mariam Afendy; Yun Fang; Youssef Younossi; Hesham Mir; Manirath Srishord
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-25       Impact factor: 11.382

4.  Primary care practitioners survey of non-alcoholic fatty liver disease.

Authors:  Adnan Said; Veronika Gagovic; Kristen Malecki; Marjory L Givens; F Javier Nieto
Journal:  Ann Hepatol       Date:  2013 Sep-Oct       Impact factor: 2.400

5.  Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.

Authors:  Stuart McPherson; Stephen F Stewart; Elsbeth Henderson; Alastair D Burt; Christopher P Day
Journal:  Gut       Date:  2010-09       Impact factor: 23.059

6.  Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.

Authors:  Paul Angulo; Elisabetta Bugianesi; Einar S Bjornsson; Phunchai Charatcharoenwitthaya; Peter R Mills; Francisco Barrera; Svanhildur Haflidadottir; Christopher P Day; Jacob George
Journal:  Gastroenterology       Date:  2013-07-13       Impact factor: 22.682

7.  Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment.

Authors:  Seong Ho Park; Pyo Nyun Kim; Kyoung Won Kim; Sang Won Lee; Seong Eon Yoon; Sung Won Park; Hyun Kwon Ha; Moon-Gyu Lee; Shin Hwang; Sung-Gyu Lee; Eun Sil Yu; Eun Yoon Cho
Journal:  Radiology       Date:  2006-02-16       Impact factor: 11.105

8.  Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease.

Authors:  Janus P Ong; Angela Pitts; Zobair M Younossi
Journal:  J Hepatol       Date:  2008-07-09       Impact factor: 25.083

9.  The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.

Authors:  Paul Angulo; Jason M Hui; Giulio Marchesini; Ellisabetta Bugianesi; Jacob George; Geoffrey C Farrell; Felicity Enders; Sushma Saksena; Alastair D Burt; John P Bida; Keith Lindor; Schuyler O Sanderson; Marco Lenzi; Leon A Adams; James Kench; Terry M Therneau; Christopher P Day
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

10.  Secondary causes of nonalcoholic fatty liver disease.

Authors:  Jacob M Kneeman; Joseph Misdraji; Kathleen E Corey
Journal:  Therap Adv Gastroenterol       Date:  2012-05       Impact factor: 4.409

  10 in total
  9 in total

1.  Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database.

Authors:  Alina M Allen; Holly K Van Houten; Lindsey R Sangaralingham; Jayant A Talwalkar; Rozalina G McCoy
Journal:  Hepatology       Date:  2018-09-20       Impact factor: 17.425

2.  Elevated prevalence of moderate-to-severe hepatic steatosis in World Trade Center General Responder Cohort in a program of CT lung screening.

Authors:  Xiangmeng Chen; Teng Ma; Rowena Yip; Ponni V Perumalswami; Andrea D Branch; Sara Lewis; Michael Crane; David F Yankelevitz; Claudia I Henschke
Journal:  Clin Imaging       Date:  2019-12-12       Impact factor: 1.605

3.  Advanced liver fibrosis and the metabolic syndrome in a primary care setting.

Authors:  Andrew D Schreiner; Jingwen Zhang; Valerie Durkalski-Mauldin; Sherry Livingston; Justin Marsden; John Bian; Patrick D Mauldin; William P Moran; Don C Rockey
Journal:  Diabetes Metab Res Rev       Date:  2021-04-09       Impact factor: 4.876

4.  Computed tomography findings of metabolic syndrome in patients with acute colonic diverticulitis.

Authors:  Mark A Anderson; Hamed Kordbacheh; Evita Joseph; Susan E Bennett; Fatima Cody Stanford; Avinash Kambadakone
Journal:  J Med Imaging Radiat Oncol       Date:  2021-02-16       Impact factor: 1.667

Review 5.  Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Fasiha Kanwal; Jay H Shubrook; Leon A Adams; Kim Pfotenhauer; Vincent Wai-Sun Wong; Eugene Wright; Manal F Abdelmalek; Stephen A Harrison; Rohit Loomba; Christos S Mantzoros; Elisabetta Bugianesi; Robert H Eckel; Lee M Kaplan; Hashem B El-Serag; Kenneth Cusi
Journal:  Gastroenterology       Date:  2021-09-20       Impact factor: 33.883

6.  Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma.

Authors:  Luis C Bertot; Gary P Jeffrey; Michael Wallace; Gerry MacQuillan; George Garas; Helena L Ching; Leon A Adams
Journal:  Hepatol Commun       Date:  2017-02-27

7.  Tagging incidental finding of fatty liver on ultrasound: A novel intervention to improve early detection of liver fibrosis.

Authors:  Navroop Nagra; Rubal Penna; Danielle La Selva; David Coy; Asma Siddique; Blaire Burman
Journal:  J Clin Transl Res       Date:  2021-09-29

8.  Identifying Patients at Risk for Fibrosis in a Primary Care NAFLD Cohort.

Authors:  Andrew D Schreiner; Sherry Livingston; Jingwen Zhang; Mulugeta Gebregziabher; Justin Marsden; David G Koch; Chelsey A Petz; Valerie L Durkalski-Mauldin; Patrick D Mauldin; William P Moran
Journal:  J Clin Gastroenterol       Date:  2021-07-22       Impact factor: 3.062

9.  The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults.

Authors:  Wen Guo; Jing Lu; Pei Qin; Xiaona Li; Wenfang Zhu; Juan Wu; Nianzhen Xu; Qun Zhang
Journal:  Lipids Health Dis       Date:  2020-10-07       Impact factor: 3.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.